Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. M. D'Armini, H. A. Ghofrani, N. H. Kim, E. Mayer, G. Simonneau, M. R. Wilkins, T. Pulido, A. Fritsch, N. Davie, M. M. Hoeper (Pavia, Italy; Giessen, Bad Nauheim, Wuppertal, Hannover, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom; Mexico City, Mexico). Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study. Eur Respir J 2013; 42: Suppl. 57, 2598

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders Source: Eur Respir J 2002; 19: 664-671 Year: 2002 Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Title: Sublingual glyceryl trinitrate vasoreactivity testing during right heart catheterization for the diagnosis of pulmonary hypertension related to left heart disease Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015